PLATO: Brilinta shows benefit over clopidogrel
02 September 2009
Alex Shimmings
Please Login to read the full article.
02 September 2009
Alex Shimmings
The newly presented full data from
AstraZeneca's PLATO study of Brilinta (ticagrelor) show that the novel oral antiplatelet therapy reduced cardiovascular events in patients with acute coronary syndromes by 11.7% compared with 9.8% for clopidogrel (Sanofi-Aventis/Bristol-Myers Squibb's...
Please Login to read the full article.
RELATED CONTENT
NEWS
- AstraZeneca heartened by US FDA nod to antiplatelet medicine Brilinta
- Brilique beats rival clopidogrel for ACS: now NICE would like Efient comparison
- J&J/Bayer to pursue secondary CV prevention in ACS label for Xarelto
- AZ's Brilique gets a two from German jury, but industry troubled by uncertainty
FEATURES
Other Informa Features
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
